These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 24462727)

  • 1. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors.
    Cote SR; Chitravanshi VC; Bleickardt C; Sapru HN; Kuzhikandathil EV
    Behav Brain Res; 2014 Apr; 263():46-50. PubMed ID: 24462727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo characterization of the agonist-dependent D3 dopamine receptor tolerance property.
    Cote SR; Kuzhikandathil EV
    Neuropharmacology; 2014 Apr; 79():359-67. PubMed ID: 24316466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral and cellular dopamine D
    Lanza K; Meadows SM; Chambers NE; Nuss E; Deak MM; Ferré S; Bishop C
    Neuropharmacology; 2018 Aug; 138():304-314. PubMed ID: 29936243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease.
    Cote SR; Kuzhikandathil EV
    Neurosci Lett; 2015 Jan; 585():33-7. PubMed ID: 25445374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat.
    Lanza K; Chemakin K; Lefkowitz S; Saito C; Chambers N; Bishop C
    Psychopharmacology (Berl); 2020 Jan; 237(1):155-165. PubMed ID: 31435690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
    Kumar R; Riddle LR; Griffin SA; Chu W; Vangveravong S; Neisewander J; Mach RH; Luedtke RR
    Neuropharmacology; 2009; 56(6-7):956-69. PubMed ID: 19371586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
    Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
    Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
    Simms SL; Huettner DP; Kortagere S
    Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
    Wang T; Duan SJ; Wang SY; Lu Y; Zhu Q; Wang LJ; Han B
    Physiol Behav; 2015 Aug; 147():193-7. PubMed ID: 25914172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.